Novel imidazopyridine derivatives as a tyrosine kinase inhibitor

2011 
PURPOSE: Novel imidazopyridine derivatives is provided to effectively supresse kinase including BTK which is mainly expressed in abnormally activated lymphocyte (B-lymphocyte and/or T lymphocyte), kinase of TEC series like ITK, BMX and RLK etc, and Janus kinase like JAK3. CONSTITUTION: A compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof is provided. Pharmaceutical composition for prevention or treatment of inflammation disease, autoimmune disease, proliferative disease, hyperproliferative disease, disease mediated with immunity, cancer and tumor comprises the compound represented by chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The inflammation disease, autoimmune disease, proliferative disease, hyperproliferative disease, disease mediated with immunity, cancer and tumor are mediated by B-lymphocyte, T lymphocyte and both of them which are abnormally activated. Pharmaceutical composition additionally includes an anti-cancer drug selected from group consisting of cell signal transduction inhibitor, mitotic inhibitor, alkyating agent, anti- metabolic agent, insertion anti-cancer drug, topoisomerase restrainer, immunotherapeutic agent, anti- hormone drug and mixture thereof.
    • Correction
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []